Expert panel calls for raising the bar in treating schizophrenia

December 20, 2004

NEW YORK, NY (December 20, 2004) — A panel of experts says doctors treating patients with schizophrenia should be targeting symptoms beyond hallucinations and delusions, and focus in on the common, but often overlooked, symptoms of depression and anxiety, as well as the inability to think clearly. Patients agree, ranking these symptoms as major concerns in a recent national survey. As a result, the expert panel, convened by MBL Communications, Inc., publishers of the trade journals Primary Psychiatry and CNS Spectrums, will be issuing a consensus statement about new treatment goals for schizophrenia.

"For decades, psychiatry has focused almost solely on managing a patient's 'positive symptoms,' such as hallucinations and delusions, because for previous treatments, that is pretty much all we had to offer," said Philip D. Harvey, PhD, professor of psychiatry at Mount Sinai School of Medicine and chief psychologist at Mount Sinai Hospital. "Today, patients and physicians should expect that more of the disease symptoms can be controlled, and that people with schizophrenia can have a more meaningful life."

With the advent of atypical antipsychotics, it is now possible to effectively treat the positive symptoms of hallucinations and delusions, as well as affective symptoms such as depression and anxiety. Furthermore, cognitive impairment (such as the inability to think clearly and difficulty concentrating) and impaired social function can also be alleviated. By targeting the broader spectrum of symptoms, these medications allow patients to function better in daily life.

"It takes time for advances in care to actually be used by physicians to benefit patients," said David Ginsberg, MD, section editor, MBL Communications, Inc. and director, Outpatient Services, Tisch Hospital Department of Psychiatry at New York University Medical Center. "The recent major advances we have seen in the treatment of schizophrenia are so important that we feel physicians need to expand upon their expectations to encompass a broader view of the patient. The development of a consensus statement is one step in that direction."

According to the survey, revealed for the first time during the panel discussion, patients report that it is "very important" for them to have the symptoms of hallucinations and delusions controlled, as well as depression and the inability to think clearly, concentrate or remember. Almost all of those surveyed (94%) believe that improved daily functioning is part of successful treatment for their illness, including the ability to work, shop and participate in hobbies as they normally would.

"Research shows that affective and cognitive symptoms have a tremendous impact on the suffering and frustrations that patients struggle with in order to cope with this difficult illness. It is these symptoms that are the greatest barriers to achieving a meaningful social and professional recovery," said Peter J. Weiden, MD, professor of psychiatry and director of the Schizophrenia Research Service at State University of New York (SUNY) Downstate Medical Center in Brooklyn. "This survey shows that patients are often ahead of their doctors in knowing the importance of affective and cognitive symptoms."

The panelists also included: Peter Buckley, MD, professor and chairman of the Department of Psychiatry and Behavioral Health at the Medical College of Georgia and Nina R. Schooler, PhD, adjunct professor of psychiatry at Georgetown University School of Medicine. Their presentations and aspects of the patient survey results will be published as a supplement in the February issues of CNS Spectrums and Primary Psychiatry.
-end-
About Schizophrenia

Schizophrenia is a seriously debilitating mental illness characterized by distortions of reality and disturbances in perception, mood, cognition, motivation, social function and motor behavior. Schizophrenia affects approximately one in every 100 people. The cause of schizophrenia is unknown, but it is believed to be the result of abnormal brain functioning. Schizophrenia is associated with changes in cognition that affect the ability to remember and to plan for achieving goals. In addition, interest and motivation are diminished and many individuals become depressed and socially withdrawn. The affective and cognitive problems associated with schizophrenia may be important factors in long-term outcome.

About MBL Communications

MBL Communications, Inc. is the independent publisher of the monthly journals Primary Psychiatry and CNS Spectrums, as well as a host of enduring material programs in conjunction with Mount Sinai School of Medicine. Primary Psychiatry - The Leading Voice of Clinical Psychiatric Medicine - is the largest circulation, peer-reviewed psychiatric journal in the United States, with a monthly circulation of over 65,000 primary care physicians and psychiatrists. Primary Psychiatry addresses the significant comorbid interface between psychiatry and primary care medicine. CNS Spectrums - The International Journal of Neuropsychiatric Medicine - is a monthly Index Medicus/MEDLINE journal designed to bridge the clinical information needs of 48,000 US-based psychiatrists and neurologists. If you would like to learn more about MBL Communications, Inc. please visit: www.mblcommunications.com.

Chandler Chicco Agency

Related Depression Articles from Brightsurf:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.

Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.

Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.

Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.

A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.

Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.

Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.

Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.

Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.

CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.

Read More: Depression News and Depression Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.